Reviews Valproate Sodium Injection


No reviews yet.

Depacon Drug Description
DEPACON®
(valproate sodium) Injection

BOX WARNING
HEPATOTOXICITY
HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER
THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL
HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL
RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPACON IS USED IN THIS
PATIENT GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP,
EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS.
THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT.
SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH
AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS
WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE
MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD
BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS.
TERATOGENICITY
VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G.,
SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING
POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK
OF INJURY TO THE FETUS. THIS IS ESPECIALLY IMPORTANT WHEN THE TREATMENT OF A
SPONTANEOUSLY REVERSIBLE CONDITION NOT ORDINARILY ASSOCIATED WITH PERMANENT
INJURY OR RISK OF DEATH (E.G., MIGRAINE) IS CONTEMPLATED. SEE WARNINGS,
INFORMATION FOR PATIENTS.
PANCREATITIS
CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN
AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC
WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED
SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS
AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR
ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION.
IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED.
ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED
AS CLINICALLY INDICATED. (See WARNINGS and
PRECAUTIONS.)

DRUG DESCRIPTION
Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate.
Valproate sodium has the following structure:








Valproate sodium has a molecular weight of 166.2. It occurs as an essentially
white and odorless, crystalline, deliquescent powder.
DEPACON solution is available in 5 mL single-dose vials for intravenous injection.
Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate
disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6
with sodium hydroxide and/or hydrochloric acid. The solution is clear and colorless.Last reviewed on RxList: 6/11/2008




Depacon Drug Description
DEPACON®
(valproate sodium) Injection

BOX WARNING
HEPATOTOXICITY
HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER
THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL
HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL
RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPACON IS USED IN THIS
PATIENT GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP,
EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS.
THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT.
SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH
AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS
WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE
MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD
BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS.
TERATOGENICITY
VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G.,
SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING
POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK
OF INJURY TO THE FETUS. THIS IS ESPECIALLY IMPORTANT WHEN THE TREATMENT OF A
SPONTANEOUSLY REVERSIBLE CONDITION NOT ORDINARILY ASSOCIATED WITH PERMANENT
INJURY OR RISK OF DEATH (E.G., MIGRAINE) IS CONTEMPLATED. SEE WARNINGS,
INFORMATION FOR PATIENTS.
PANCREATITIS
CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN
AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC
WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED
SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS
AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR
ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION.
IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED.
ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED
AS CLINICALLY INDICATED. (See WARNINGS and
PRECAUTIONS.)

DRUG DESCRIPTION
Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate.
Valproate sodium has the following structure:








Valproate sodium has a molecular weight of 166.2. It occurs as an essentially
white and odorless, crystalline, deliquescent powder.
DEPACON solution is available in 5 mL single-dose vials for intravenous injection.
Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate
disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6
with sodium hydroxide and/or hydrochloric acid. The solution is clear and colorless.Last reviewed on RxList: 6/11/2008




Depacon Drug Description
DEPACON®
(valproate sodium) Injection

BOX WARNING
HEPATOTOXICITY
HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER
THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL
HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL
RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPACON IS USED IN THIS
PATIENT GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP,
EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS.
THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT.
SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH
AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS
WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE
MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD
BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS.
TERATOGENICITY
VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G.,
SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING
POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK
OF INJURY TO THE FETUS. THIS IS ESPECIALLY IMPORTANT WHEN THE TREATMENT OF A
SPONTANEOUSLY REVERSIBLE CONDITION NOT ORDINARILY ASSOCIATED WITH PERMANENT
INJURY OR RISK OF DEATH (E.G., MIGRAINE) IS CONTEMPLATED. SEE WARNINGS,
INFORMATION FOR PATIENTS.
PANCREATITIS
CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN
AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC
WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED
SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS
AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR
ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION.
IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED.
ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED
AS CLINICALLY INDICATED. (See WARNINGS and
PRECAUTIONS.)

DRUG DESCRIPTION
Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate.
Valproate sodium has the following structure:








Valproate sodium has a molecular weight of 166.2. It occurs as an essentially
white and odorless, crystalline, deliquescent powder.
DEPACON solution is available in 5 mL single-dose vials for intravenous injection.
Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate
disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6
with sodium hydroxide and/or hydrochloric acid. The solution is clear and colorless.Last reviewed on RxList: 6/11/2008




Depacon Drug Description
DEPACON®
(valproate sodium) Injection

BOX WARNING
HEPATOTOXICITY
HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER
THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL
HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL
RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPACON IS USED IN THIS
PATIENT GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP,
EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS.
THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT.
SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH
AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS
WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE
MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD
BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS.
TERATOGENICITY
VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G.,
SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING
POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK
OF INJURY TO THE FETUS. THIS IS ESPECIALLY IMPORTANT WHEN THE TREATMENT OF A
SPONTANEOUSLY REVERSIBLE CONDITION NOT ORDINARILY ASSOCIATED WITH PERMANENT
INJURY OR RISK OF DEATH (E.G., MIGRAINE) IS CONTEMPLATED. SEE WARNINGS,
INFORMATION FOR PATIENTS.
PANCREATITIS
CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN
AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC
WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED
SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS
AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR
ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION.
IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED.
ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED
AS CLINICALLY INDICATED. (See WARNINGS and
PRECAUTIONS.)

DRUG DESCRIPTION
Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate.
Valproate sodium has the following structure:








Valproate sodium has a molecular weight of 166.2. It occurs as an essentially
white and odorless, crystalline, deliquescent powder.
DEPACON solution is available in 5 mL single-dose vials for intravenous injection.
Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate
disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6
with sodium hydroxide and/or hydrochloric acid. The solution is clear and colorless.Last reviewed on RxList: 6/11/2008




Depacon Drug Description
DEPACON®
(valproate sodium) Injection

BOX WARNING
HEPATOTOXICITY
HEPATIC FAILURE RESULTING IN FATALITIES HAS OCCURRED IN PATIENTS RECEIVING
VALPROIC ACID AND ITS DERIVATIVES. EXPERIENCE HAS INDICATED THAT CHILDREN UNDER
THE AGE OF TWO YEARS ARE AT A CONSIDERABLY INCREASED RISK OF DEVELOPING FATAL
HEPATOTOXICITY, ESPECIALLY THOSE ON MULTIPLE ANTICONVULSANTS, THOSE WITH CONGENITAL METABOLIC DISORDERS, THOSE WITH SEVERE SEIZURE DISORDERS ACCOMPANIED BY MENTAL
RETARDATION, AND THOSE WITH ORGANIC BRAIN DISEASE. WHEN DEPACON IS USED IN THIS
PATIENT GROUP, IT SHOULD BE USED WITH EXTREME CAUTION AND AS A SOLE AGENT. THE
BENEFITS OF THERAPY SHOULD BE WEIGHED AGAINST THE RISKS. ABOVE THIS AGE GROUP,
EXPERIENCE IN EPILEPSY HAS INDICATED THAT THE INCIDENCE OF FATAL HEPATOTOXICITY
DECREASES CONSIDERABLY IN PROGRESSIVELY OLDER PATIENT GROUPS.
THESE INCIDENTS USUALLY HAVE OCCURRED DURING THE FIRST SIX MONTHS OF TREATMENT.
SERIOUS OR FATAL HEPATOTOXICITY MAY BE PRECEDED BY NON-SPECIFIC SYMPTOMS SUCH
AS MALAISE, WEAKNESS, LETHARGY, FACIAL EDEMA, ANOREXIA, AND VOMITING. IN PATIENTS
WITH EPILEPSY, A LOSS OF SEIZURE CONTROL MAY ALSO OCCUR. PATIENTS SHOULD BE
MONITORED CLOSELY FOR APPEARANCE OF THESE SYMPTOMS. LIVER FUNCTION TESTS SHOULD
BE PERFORMED PRIOR TO THERAPY AND AT FREQUENT INTERVALS THEREAFTER, ESPECIALLY
DURING THE FIRST SIX MONTHS.
TERATOGENICITY
VALPROATE CAN PRODUCE TERATOGENIC EFFECTS SUCH AS NEURAL TUBE DEFECTS (E.G.,
SPINA BIFIDA). ACCORDINGLY, THE USE OF VALPROATE PRODUCTS IN WOMEN OF CHILDBEARING
POTENTIAL REQUIRES THAT THE BENEFITS OF ITS USE BE WEIGHED AGAINST THE RISK
OF INJURY TO THE FETUS. THIS IS ESPECIALLY IMPORTANT WHEN THE TREATMENT OF A
SPONTANEOUSLY REVERSIBLE CONDITION NOT ORDINARILY ASSOCIATED WITH PERMANENT
INJURY OR RISK OF DEATH (E.G., MIGRAINE) IS CONTEMPLATED. SEE WARNINGS,
INFORMATION FOR PATIENTS.
PANCREATITIS
CASES OF LIFE-THREATENING PANCREATITIS HAVE BEEN REPORTED IN BOTH CHILDREN
AND ADULTS RECEIVING VALPROATE. SOME OF THE CASES HAVE BEEN DESCRIBED AS HEMORRHAGIC
WITH A RAPID PROGRESSION FROM INITIAL SYMPTOMS TO DEATH. CASES HAVE BEEN REPORTED
SHORTLY AFTER INITIAL USE AS WELL AS AFTER SEVERAL YEARS OF USE. PATIENTS
AND GUARDIANS SHOULD BE WARNED THAT ABDOMINAL PAIN, NAUSEA, VOMITING, AND/OR
ANOREXIA CAN BE SYMPTOMS OF PANCREATITIS THAT REQUIRE PROMPT MEDICAL EVALUATION.
IF PANCREATITIS IS DIAGNOSED, VALPROATE SHOULD ORDINARILY BE DISCONTINUED.
ALTERNATIVE TREATMENT FOR THE UNDERLYING MEDICAL CONDITION SHOULD BE INITIATED
AS CLINICALLY INDICATED. (See WARNINGS and
PRECAUTIONS.)

DRUG DESCRIPTION
Valproate sodium is the sodium salt of valproic acid designated as sodium 2-propylpentanoate.
Valproate sodium has the following structure:








Valproate sodium has a molecular weight of 166.2. It occurs as an essentially
white and odorless, crystalline, deliquescent powder.
DEPACON solution is available in 5 mL single-dose vials for intravenous injection.
Each mL contains valproate sodium equivalent to 100 mg valproic acid, edetate
disodium 0.40 mg, and water for injection to volume. The pH is adjusted to 7.6
with sodium hydroxide and/or hydrochloric acid. The solution is clear and colorless.Last reviewed on RxList: 6/11/2008





Other reviews about Valproate Sodium Injection on wordpress

Saint Vitus's Dance
  by Mo
After writing this recent post about Fyodor Dostoyevsky's epilepsy, I decided it was time I re-read one of the great author's novels, and chose The Idiot, because it […]


Focus- related epilepsies
  by Yasser Metwally
The author: Professor Yasser Metwally http://yassermetwally.com INTRODUCTION It was stated that a spike focus does not necessarily denote a stable epileptogenic focus; benign Rolandic epilepsy stands as the epitome of the […]


Trigeminal neuralgia
  by Yasser Metwally
The author: Professor Yasser Metwally http://yassermetwally.com INTRODUCTION Background: Trigeminal neuralgia (TN) is a common and potentially disabling pain syndrome, the precise pathophysiology of which remains obscure. Although neurologic examination findings are normal in […]


Continuing Education Geriatrics In Nursing Online- Us
  by magrabota


PHARMACOLOGY MNEMONICS
  by doctorstube
Pulmonary infiltrations inducing drugs "Go BAN Me!":GoldBleomycin/ Busulphan/ BCNUAmiodarone/ Acyclovir/ AzathioprineNitrofurantoinMelphalan/ Methotrexate/ Methysergide MPTP: mechanism, effect MPTP:Mitochondrial Parkinson's-Type Poison.· A mitochondrial poison that elicits a Parkinson's-type effect. Antimuscarinics: […]


Migraine Treatment
  by Lileya
Headache Day 6. Migraine attacks usually last between 4 - 72 hours. I've had weird and interesting headaches since childhood and have accumulated a whole bunch of diagnostic […]


Pfizer - Products
  by El Horror
Web Banners Products 2004 - FDA approves Spiriva HandiHaler (tiotropium bromide inhalation powder) for the long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease, which includes chronic bronchitis […]


Management of Bipolar Disorders
  by abukalya
Introduction Bipolar disorder is a disorder of mood, in which a person has episodes of both elevated and depressed mood. These episodes of major change of mood are associated […]


Drug Updates
  by bookjunglejm
Telavancin (Vibativ) An antibiotic used to treat complicated skin and skin-structure infections caused by susceptible gram-positive organisms Special considerations • Women of childbearing age should have a pregnancy test before therapy. […]


The classifcation of drugs used in psychiatry
  by kraeplinpsychiatry
Page 517 Chapter 21 Anxiolytic drugs 526 Hypnotics 529 Antipsychotic drugs 530 Antiparkinsonian drugs 539 Antidepressant drugs 540 Mood-stabilizing drugs 557 Psychostimulants 564 518 Chapter contents History of physical treatments General considerations 519 The pharmacokinetics of psychotropic drugs 519 General […]



Other reviews about Valproate Sodium Injection on web:

Intravenous injection – Epilim Intravenous by Sanofi-Aventis. Extended release tablets – Epilim Chrono by Sanofi-Aventis. A combination of sodium valproate and valproic acid in a 2 ... Sodium valproate - Wikipedia, the free encyclopedia


Consumer information about the medication VALPROATE SODIUM - INJECTION (Depacon), includes side effects, drug interactions, recommended dosages, and storage information. Read ... VALPROATE SODIUM - INJECTION (Depacon) side effects, medical uses ...


Learn about the prescription medication Depacon (Valproate Sodium Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Depacon (Valproate Sodium Injection) Drug Information: Uses, Side ...


Valproate Sodium Solution for injection To return to the main entry click here . What is this medicine? VALPROATE SODIUM (val PRO ate SO dee um) Valproate Sodium Solution for injection: Information from Answers.com


Back to List. Title: Author: Date: Source: Intravenous Valproate Sodium Injection For Prolonged Migraine Headache Lawrence Robbins, MD Posted February 2000 Intravenous Valproate Sodium Injection For Prolonged Migraine Headache


valproate sodium-injection glossary includes a list of valproate sodium-injection related medical definitions and related links on MedicineNet.com valproate sodium-injection Glossary of Terms with Definitions on ...


Learn all about Valproate sodium (Injection). Valproate Sodium (VAL-proe-ate SOE-dee-um) Treats different types of seizures (epilepsy). This medicine is an anticonvulsant. Valproate sodium (Injection) - Drug Information


Valproate Sodium Injection Dosage - Free tips, articles, expert advice, videos, communities and more. Valproate Sodium Injection Dosage - Wellsphere


Abbott Depacon (valproate sodium injection) ... Product information specific to a particular country is available at the Web site(s) below. Depacon


45982a/revised: july 2006 valproate sodium injection rx only box warning hepatotoxicity hepatic failure resulting in fatalities has occurred in patients receiving valproic acid and its ... BOX WARNING





Featured Reviews

Reviews Cocaine

Cocaine Drug Description Cocaine Hydrochloride Topical Solution NOT FOR INJECTION OR OPHTHALMIC USE. DRUG DESCRIPTION Each mL contains: Cocaine Hydrochloride 40 mg or 100 mg As aqueous solution. The topical solution contains...
Read More  |  Review This
Reviews Pylera Capsules

Pylera Capsules Drug Description PYLERA™ Capsules (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) 140 mg/125 mg/125 mg To reduce the development of drug-resistant bacteria and maintain the effectiveness...
Read More  |  Review This
Reviews Raltegravir Tablets

Isentress Drug Description ISENTRESS (raltegravir) Tablets DRUG DESCRIPTION What are the possible side effects of raltegravir (Isentress)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Je-Vax

Je-Vax Drug Description JE-VAX® Japanese Encephalitis Virus Vaccine Inactivated DRUG DESCRIPTION What are the possible side effects of this vaccine (Je-Vax)? You should not receive a booster vaccine if you had a life-threatening...
Read More  |  Review This
Reviews Desloratadine

Clarinex Drug Description CLARINEX® (desloratadine) Tablets, Syrup, Reditabs® Tablets DRUG DESCRIPTION What are the possible side effects of desloratadine (Clarinex, Clarinex Reditabs)? Get emergency medical help if you...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....